Rehabilitation for chronic neurological disorders including acquired brain injury | Draft guidance consultation | NICE guideline | |
Pneumonia: diagnosis and management (update) | Draft guidance consultation | NICE guideline | |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Draft guidance | Technology appraisal guidance | |
PillCam COLON 2 for investigation of the colon through direct visualisation | Diagnostics consultation | Diagnostics guidance | |
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Draft guidance | Technology appraisal guidance | |
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Draft guidance | Technology appraisal guidance | |
Cataracts in adults: management | Surveillance consultation | NICE guideline | |
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Draft guidance | Technology appraisal guidance | |
Nemolizumab for treating prurigo nodularis [ID6451] | Draft guidance | Technology appraisal guidance | |
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Draft guidance | Technology appraisal guidance | |